Testing effectiveness (Phase 2)UnknownNCT05147493
What this trial is testing
Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Who this might be right for
Multiple MyelomaRenal ImpairmentNeoplasms, Plasma Cell+5 more
Hellenic Society of Hematology 51